111 Group 2018 Revenue Of 1 Billion 786 Million Yuan Will Expand The B2B Plate

Recently, the 1 drug network parent company 111 group released the first annual performance announcement after listing. In 2018, the 111 group achieved 1 billion 786 million yuan in revenue, an increase of 86% over the same period last year, and net loss accounted for 41.6% of its income from 21.4% in 2016 to 21.4% in 2018.

It is understood that in 2018, the 111 group B2B plate "1 drug city" revenue reached 923 million yuan, an increase of 962% over last year.

B2B revenue accounted for 51.6% of the group's total revenue, the main force for revenue growth.

Mainly due to the 1 drug city since its establishment in 2017, it has been committed to providing diversified services for drugstores. As of the end of 2018, the number of drugstores served has exceeded 15.

B2C Edition business remained stable, with annual revenue of 847 million yuan, mainly due to the 111 group in 2018 to further improve the distribution network covering the whole country.

In addition, the company's service revenue reached 15 million 740 thousand yuan, an increase of 53.3% over the same period, mainly from the pharmaceutical marketing and service revenue.

Data show that as of the end of 2018, the 111 group has established direct mining strategic cooperation with 93 well-known pharmaceutical companies at home and abroad.

In addition, it has built a regional center in four places such as Guangzhou, East China's Kunshan, North China's Tianjin, southwest Chongqing and other places in Southern China, which can provide services to the major cities in 23 provinces in 24 hours and provide services to the whole country within 72 hours.

The 111 group said it will continue to strengthen the B2B business sector in 2019 and expand the virtual drugstore network. The goal is to add 8 000 drugstores to form a network layout covering 23 000 pharmacies across the country, and selectively build additional centers to enhance operational efficiency while increasing geographic coverage.

At the same time, it will continue to establish direct strategic cooperation with more large pharmaceutical companies at home and abroad.